A new publication involving thymosin alpha-1 was listed on November 1, 2026. The paper, titled "A novel porcine interleukin-2-interferon-alpha-thymosin alpha1 tripartite fusion protein confers antiviral activity against pseudorabies virus," appeared in the journal Veterinary Microbiology.
The publication describes a tripartite fusion protein combining porcine interleukin-2, interferon-alpha, and thymosin alpha-1. According to the listing, the work relates to antiviral activity against pseudorabies virus in a veterinary research context.
Thymosin alpha-1 remains classified as an unapproved research compound. This publication record does not state clinical application, approval status, or human use. No efficacy outcomes, dosing information, or safety conclusions are included in this brief beyond the title and journal listing provided.
Readers interested in further detail should consult the original publication through the source link provided. For background on thymosin alpha-1 generally, see the compound overview linked with this brief.